<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31010179</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Antiviral Activities of Silymarin and Derivatives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules24081552</ELocationID><Abstract><AbstractText>Silymarin flavonolignans are well-known agents that typically possess antioxidative, anti-inflammatory, and hepatoprotective functions. Recent studies have also documented the antiviral activities of silymarin and its derivatives against several viruses, including the flaviviruses (hepatitis C virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus), influenza virus, human immunodeficiency virus, and hepatitis B virus. This review will describe some of the latest preclinical and clinical studies detailing the antiviral profiles of silymarin and its derivatives, and discuss their relevance for antiviral drug development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ching-Hsuan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. julia.chliu@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada. julia.chliu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jassey</LastName><ForeName>Alagie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. alagie_jassey@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Hsin-Ya</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. jg930727@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Liang-Tzung</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. ltlin@tmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. ltlin@tmu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST107-2320-B-038-034-MY3</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044947">Flavonolignans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012838">Silymarin</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002646" MajorTopicYN="N">Chikungunya virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005416" MajorTopicYN="N">Flavivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044947" MajorTopicYN="N">Flavonolignans</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012838" MajorTopicYN="N">Silymarin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014035" MajorTopicYN="N">Togaviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">drug development</Keyword><Keyword MajorTopicYN="N">flavonolignans</Keyword><Keyword MajorTopicYN="N">silymarin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31010179</ArticleId><ArticleId IdType="pmc">PMC6514695</ArticleId><ArticleId IdType="doi">10.3390/molecules24081552</ArticleId><ArticleId IdType="pii">molecules24081552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Federico A., Dallio M., Loguercio C., Tsai T.-H., Jeon Y. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22:191. doi: 10.3390/molecules22020191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22020191</ArticleId><ArticleId IdType="pmc">PMC6155865</ArticleId><ArticleId IdType="pubmed">28125040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit N., Kohli K., Ahmad S., Baboota S., Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J. Pharmacol. 2007;39:172. doi: 10.4103/0253-7613.36534.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0253-7613.36534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules. 2017;22:1942. doi: 10.3390/molecules22111942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22111942</ArticleId><ArticleId IdType="pmc">PMC6150307</ArticleId><ArticleId IdType="pubmed">29125572</ArticleId></ArticleIdList></Reference><Reference><Citation>Strader D.B., Bacon B.R., Lindsay K.L., Brecque D.R., Morgan T., Wright E.C., Allen J., Khokar M.F., Hoofnagle J.H., Seeff L.B., et al. Use of complementary and alternative medicine in patients with liver disease. Am. J. Gastroenterol. 2002;97:2391&#x2013;2397. doi: 10.1111/j.1572-0241.2002.05993.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2002.05993.x</ArticleId><ArticleId IdType="pubmed">12358262</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Silibinin-C-2&#x2032;,3-dihydrogensuccinate, Disodium Salt for the Prevention of Recurrent Hepatitis C in Liver Transplant Recipients.  [(accessed on 23 March 2019)]; Available online:  https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu310828.</Citation></Reference><Reference><Citation>Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin. Liver Dis. 2000;20:17&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10895429</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco L., Palacios G., Martinez J.A., V&#xe1;zquez A., Savji N., De Ory F., Sanchez-Seco M.P., Mart&#xed;n D., Lipkin W.I., Tenorio A. First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa. PLoS Negl. Trop. Dis. 2011;5:e1251. doi: 10.1371/journal.pntd.0001251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001251</ArticleId><ArticleId IdType="pmc">PMC3149010</ArticleId><ArticleId IdType="pubmed">21829739</ArticleId></ArticleIdList></Reference><Reference><Citation>Polyak S.J., Morishima C., Shuhart M.C., Wang C.C., Liu Y., Lee D.Y. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-&#x3ba;B Signaling, and HCV Infection by Standardized Silymarin. Gastroenterology. 2007;132:1925&#x2013;1936. doi: 10.1053/j.gastro.2007.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.02.038</ArticleId><ArticleId IdType="pubmed">17484885</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima C., Lohmann V., Pal S., Liu Y., Polyak S.J., Lee D.Y.W., Graf T.N., Oberlies N. Identification of hepatoprotective flavonolignans from silymarin. Proc. Natl. Acad. Sci. USA. 2010;107:5995&#x2013;5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851903</ArticleId><ArticleId IdType="pubmed">20231449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagoner J., Negash A., Kane O.J., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology. 2010;51:1912&#x2013;1921. doi: 10.1002/hep.23587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23587</ArticleId><ArticleId IdType="pmc">PMC2909978</ArticleId><ArticleId IdType="pubmed">20512985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed&#x2013;Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R., Pawlotsky J. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology. 2010;138:1112&#x2013;1122. doi: 10.1053/j.gastro.2009.11.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.11.053</ArticleId><ArticleId IdType="pubmed">19962982</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaising J., L&#xe9;vy P.L., Gondeau C., Phelip C., Varbanov M., Teissier E., Ruggiero F., Polyak S.J., Oberlies N.H., Ivanovic T., et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 2013;15:1866&#x2013;1882. doi: 10.1111/cmi.12155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12155</ArticleId><ArticleId IdType="pubmed">23701235</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser-Nobis K., Romero-Brey I., Ganten T.M., Gouttenoire J., Harak C., Klein R., Schemmer P., Binder M., Schnitzler P., Moradpour D., et al. Analysis of hepatitis C virus resistance to Silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology. 2013;57:953&#x2013;963. doi: 10.1002/hep.26260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26260</ArticleId><ArticleId IdType="pmc">PMC3593759</ArticleId><ArticleId IdType="pubmed">23322644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons. J. Virol. 2003;77:5487&#x2013;5492. doi: 10.1128/JVI.77.9.5487-5492.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.9.5487-5492.2003</ArticleId><ArticleId IdType="pmc">PMC153965</ArticleId><ArticleId IdType="pubmed">12692249</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.H., Lin C.C., Hsu W.C., Chung C.Y., Lin C.C., Jassey A., Chang S.P., Tai C.J., Tai C.J., Shields J., et al. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut. 2017;66:1853&#x2013;1861. doi: 10.1136/gutjnl-2016-312019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312019</ArticleId><ArticleId IdType="pubmed">27436270</ArticleId></ArticleIdList></Reference><Reference><Citation>DebRoy S., Hiraga N., Imamura M., Hayes C.N., Akamatsu S., Canini L., Perelson A.S., Pohl R.T., Persiani S., Uprichard S.L. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J. Viral Hepat. 2016;23:708&#x2013;717. doi: 10.1111/jvh.12551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.12551</ArticleId><ArticleId IdType="pmc">PMC4974116</ArticleId><ArticleId IdType="pubmed">27272497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagoner J., Morishima C., Graf T.N., Oberlies N.H., Teissier E., P&#xe9;cheur E.-I., Tavis J.E., Polyak S.J. Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation. PLoS ONE. 2011;6:e16464. doi: 10.1371/journal.pone.0016464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016464</ArticleId><ArticleId IdType="pmc">PMC3030583</ArticleId><ArticleId IdType="pubmed">21297992</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaddir I., Rasool N., Hussain W., Mahmood S. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies. J. Vector Borne Dis. 2017;54:255.</Citation><ArticleIdList><ArticleId IdType="pubmed">29097641</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann. N. Y. Acad. Sci. 2014;1323:115&#x2013;139. doi: 10.1111/nyas.12462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12462</ArticleId><ArticleId IdType="pmc">PMC4159436</ArticleId><ArticleId IdType="pubmed">24891213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Sugaya N., Hirotsu N., Lee N., De Jong M.D., Hurt A.C., Ishida T., Sekino H., Yamada K., Portsmouth S., et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N. Engl. J. Med. 2018;379:913&#x2013;923. doi: 10.1056/NEJMoa1716197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716197</ArticleId><ArticleId IdType="pubmed">30184455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ga&#x17e;&#xe1;k R., Purchartov&#xe1; K., Marhol P., &#x17d;ivn&#xe1; L., Sedmera P., Valentova K., Kato N., Matsumura H., Kaihatsu K., K&#x159;en V. Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur. J. Med. Chem. 2010;45:1059&#x2013;1067. doi: 10.1016/j.ejmech.2009.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2009.11.056</ArticleId><ArticleId IdType="pubmed">20036447</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J., Choi H. Silymarin efficacy against influenza A virus replication. Phytomedicine. 2011;18:832&#x2013;835. doi: 10.1016/j.phymed.2011.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2011.01.026</ArticleId><ArticleId IdType="pubmed">21377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai J.-P., Wu L.-Q., Li R., Zhao X.-F., Wan Q.-Y., Chen X.-X., Li W.-Z., Wang G.-F., Li K.-S. Identification of 23-(S)-2-Amino-3-Phenylpropanoyl-Silybin as an Antiviral Agent for Influenza A Virus Infection In Vitro and In Vivo. Antimicrob. Agents Chemother. 2013;57:4433&#x2013;4443. doi: 10.1128/AAC.00759-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00759-13</ArticleId><ArticleId IdType="pmc">PMC3754338</ArticleId><ArticleId IdType="pubmed">23836164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis. 1999;20:2101&#x2013;2108. doi: 10.1093/carcin/20.11.2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/20.11.2101</ArticleId><ArticleId IdType="pubmed">10545412</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe B., Hall W.W. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev. Mol. Med. 2008;10:10. doi: 10.1017/S1462399408000847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1462399408000847</ArticleId><ArticleId IdType="pubmed">18928579</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure J., Lovelace E.S., Elahi S., Maurice N.J., Wagoner J., Dragavon J., Mittler J.E., Kraft Z., Stamatatos L., Horton H., et al. Correction: Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation. PLoS ONE. 2012;7:41832. doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458</ArticleId><ArticleId IdType="pmc">PMC3404953</ArticleId><ArticleId IdType="pubmed">22848626</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure J., Margineantu D.H., Sweet I.R., Polyak S.J. Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism. Virology. 2014;449:96&#x2013;103. doi: 10.1016/j.virol.2013.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.11.003</ArticleId><ArticleId IdType="pmc">PMC3909448</ArticleId><ArticleId IdType="pubmed">24418542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lani R., Hassandarvish P., Chiam C.W., Moghaddam E., Chu J.J.H., Rausalu K., Merits A., Higgs S., VanLandingham D., Abu Bakar S., et al. Antiviral activity of silymarin against chikungunya virus. Sci. Rep. 2015;5:11421. doi: 10.1038/srep11421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11421</ArticleId><ArticleId IdType="pmc">PMC4468427</ArticleId><ArticleId IdType="pubmed">26078201</ArticleId></ArticleIdList></Reference><Reference><Citation>Camini F.C., Da Silva T.F., Caetano C.C.D.S., Almeida L.T., Ferraz A.C., Vitoreti V.M.A., Silva B.D.M., Silva S.D.Q., De Magalh&#xe3;es J.C., Magalh&#xe3;es C.L.D.B. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress. Antivir. Res. 2018;158:8&#x2013;12. doi: 10.1016/j.antiviral.2018.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.07.023</ArticleId><ArticleId IdType="pubmed">30076863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun S., Lee S., Ventura W.R., McMenamin J. Knowledge, Awareness, and Prevention of Hepatitis B Virus Infection Among Korean American Parents. J. Immigr. Minor. Heal. 2017;20:943&#x2013;950. doi: 10.1007/s10903-017-0609-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-017-0609-1</ArticleId><ArticleId IdType="pmc">PMC6061079</ArticleId><ArticleId IdType="pubmed">28639095</ArticleId></ArticleIdList></Reference><Reference><Citation>Umetsu T., Inoue J., Kogure T., Kakazu E., Ninomiya M., Iwata T., Takai S., Nakamura T., Sano A., Shimosegawa T. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem. Biophys. Rep. 2018;14:20&#x2013;25. doi: 10.1016/j.bbrep.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC5986624</ArticleId><ArticleId IdType="pubmed">29872730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.-F., Fu S.-L., Kao C.-H., Yang C.-W., Lin C.-H., Hsu M.-T., Tsai T.-F. Chemopreventive Effect of Silymarin on Liver Pathology in HBV X Protein Transgenic Mice. Cancer Res. 2008;68:2033&#x2013;2042. doi: 10.1158/0008-5472.CAN-07-2450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2450</ArticleId><ArticleId IdType="pubmed">18339886</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanamly M., Tadros F., Labeeb S., Makld H., Mikhail N., Abdel-Hamid M., Shehata M., Abu-Baki L., Medhat A., Magder L., et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: Study description and 12-month results. Dig. Liver Dis. 2004;36:752&#x2013;759. doi: 10.1016/j.dld.2004.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2004.06.015</ArticleId><ArticleId IdType="pubmed">15571006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbay E., Zigmond E., Pappo O., Hemed N., Rowe M., Zabrecky G., Cohen R., Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial. World J. Gastroenterol. 2007;13:5317&#x2013;5323. doi: 10.3748/wjg.v13.i40.5317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v13.i40.5317</ArticleId><ArticleId IdType="pmc">PMC4171320</ArticleId><ArticleId IdType="pubmed">17879400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried M.W., Navarro V.J., Afdhal N., Belle S.H., Wahed A.S., Hawke R.L., Doo E., Meyers C.M., Reddy K.R., Silymarin N., et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA. 2012;308:274&#x2013;282. doi: 10.1001/jama.2012.8265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.8265</ArticleId><ArticleId IdType="pmc">PMC3683986</ArticleId><ArticleId IdType="pubmed">22797645</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaguarnera M., Motta M., Vacante M., Malaguarnera G., Caraci F., Nunnari G., Gagliano C., Greco C., Chisari G., Drago F., et al. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Am. J. Transl. Res. 2015;7:2510&#x2013;2518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4697727</ArticleId><ArticleId IdType="pubmed">26807195</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaguarnera G., Bertino G., Chisari G., Motta M., Vecchio M., Vacante M., Caraci F., Greco C., Drago F., Nunnari G., et al. Silybin supplementation during HCV therapy with pegylated interferon-&#x3b1; plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry. 2016;16:398. doi: 10.1186/s12888-016-1115-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-016-1115-z</ArticleId><ArticleId IdType="pmc">PMC5109776</ArticleId><ArticleId IdType="pubmed">27842532</ArticleId></ArticleIdList></Reference><Reference><Citation>Loguercio C., Festi D., Loguercio C. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. 2011;17:2288&#x2013;2301. doi: 10.3748/wjg.v17.i18.2288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i18.2288</ArticleId><ArticleId IdType="pmc">PMC3098397</ArticleId><ArticleId IdType="pubmed">21633595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., Sch&#xf6;niger&#x2013;Hekele M., Holzmann H., Steindl&#x2013;Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561&#x2013;1567. doi: 10.1053/j.gastro.2008.07.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.07.072</ArticleId><ArticleId IdType="pubmed">18771667</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj J., Dahari H., Pohl R.-T., Ferenci P., Perelson A.S. Understanding silibinin&#x2019;s modes of action against HCV using viral kinetic modeling. J. Hepatol. 2012;56:1019&#x2013;1024. doi: 10.1016/j.jhep.2011.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2011.12.012</ArticleId><ArticleId IdType="pmc">PMC3328661</ArticleId><ArticleId IdType="pubmed">22245888</ArticleId></ArticleIdList></Reference><Reference><Citation>Biermer M., Berg T. Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin Plus Ribavirin. Gastroenterology. 2009;137:390&#x2013;391. doi: 10.1053/j.gastro.2009.02.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.02.087</ArticleId><ArticleId IdType="pubmed">19486953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutter K., Scherzer T.-M., Beinhardt S., Kerschner H., St&#xe4;ttermayer A.F., Hofer H., Popow-Kraupp T., Steindl-Munda P., Ferenci P. Intravenous silibinin as &#x2018;rescue treatment&#x2019; for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir. Ther. 2011;16:1327&#x2013;1333. doi: 10.3851/IMP1942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1942</ArticleId><ArticleId IdType="pubmed">22155914</ArticleId></ArticleIdList></Reference><Reference><Citation>Biermer M., Schlosser B., F&#xfc;l&#xf6;p B., van B&#xf6;mmel F., Brodzinski A., Heyne R., Keller K., Sarrazin C., Berg T. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J. Viral Hepat. 2012;19:547&#x2013;553. doi: 10.1111/j.1365-2893.2011.01572.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2011.01572.x</ArticleId><ArticleId IdType="pubmed">22762138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahari H., Shteingart S., Gafanovich I., Cotler S.J., D&#x2019;Amato M., Pohl R.T., Weiss G., Ashkenazi Y.J., Tichler T., Goldin E., et al. Sustained virological response with intravenous silibinin: Individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. 2015;35:289&#x2013;294. doi: 10.1111/liv.12692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.12692</ArticleId><ArticleId IdType="pmc">PMC4304917</ArticleId><ArticleId IdType="pubmed">25251042</ArticleId></ArticleIdList></Reference><Reference><Citation>Verna E.C., Brown R.S., Jr. Hepatitis C Virus Infection in Liver Transplant Candidates and Recipients.  [(accessed on 10 March 2019)]; Available online:  https://www.uptodate.com/contents/hepatitis-c-virus-infection-in-liver-transplant-candidates-and-recipients.</Citation></Reference><Reference><Citation>Neumann U., Biermer M., Eurich D., Neuhaus P., Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J. Hepatol. 2010;52:951&#x2013;952. doi: 10.1016/j.jhep.2010.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.02.002</ArticleId><ArticleId IdType="pubmed">20413176</ArticleId></ArticleIdList></Reference><Reference><Citation>Beinhardt S., Rasoul-Rockenschaub S., Scherzer T.M., Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J. Hepatol. 2011;54:591&#x2013;592. doi: 10.1016/j.jhep.2010.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.09.009</ArticleId><ArticleId IdType="pubmed">21106270</ArticleId></ArticleIdList></Reference><Reference><Citation>Eurich D., Bahra M., Berg T., Boas-Knoop S., Biermer M., Neuhaus R., Neuhaus P., Neumann U. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp. Clin. Transplant. 2011;9:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21605016</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghemo A., Bhoori S., De Nicola S., Mazzaferro V., Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat. Mon. 2012;12:411&#x2013;414. doi: 10.5812/hepatmon.6135.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/hepatmon.6135</ArticleId><ArticleId IdType="pmc">PMC3412559</ArticleId><ArticleId IdType="pubmed">22879832</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapstein J., W&#xf6;rns A.M., Galle P.R., Zimmermann T. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: A case report. J. Med. Case Rep. 2014;8:257. doi: 10.1186/1752-1947-8-257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-1947-8-257</ArticleId><ArticleId IdType="pmc">PMC4110930</ArticleId><ArticleId IdType="pubmed">25047566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari&#xf1;o Z., Crespo G., D&#x2019;Amato M., Brambilla N., Giacovelli G., Rovati L., Costa J., Navasa M., Forns X. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J. Hepatol. 2013;58:415&#x2013;420. doi: 10.1016/j.jhep.2012.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2012.09.034</ArticleId><ArticleId IdType="pubmed">23063567</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendina M., D&#x2019;Amato M., Castellaneta A., Castellaneta N.M., Brambilla N., Giacovelli G., Rovati L., Rizzi S.F., Zappimbulso M., Bringiotti R.S., et al. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: A randomized clinical trial. Transpl. Int. 2014;27:696&#x2013;704. doi: 10.1111/tri.12324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12324</ArticleId><ArticleId IdType="pubmed">24673819</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;rcena R., Moreno A., Rodriguez-Gandia M.A., Albillos A., Arocena C., Blesa C., Garc&#xed;a-Hoz F., Graus J., Nu&#xf1;o J., L&#xf3;pez-Herv&#xe1;s P., et al. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J. Hepatol. 2013;58:421&#x2013;426. doi: 10.1016/j.jhep.2012.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2012.10.009</ArticleId><ArticleId IdType="pubmed">23073223</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier I., Wu G.Y., Maier G.Y.W.I. Hepatitis C and HIV co-infection: A review. World J. Gastroenterol. 2002;8:577&#x2013;579. doi: 10.3748/wjg.v8.i4.577.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v8.i4.577</ArticleId><ArticleId IdType="pmc">PMC4656301</ArticleId><ArticleId IdType="pubmed">12174359</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner E.G. Update in HIV/HCV Co-Infection in the Direct Acting Antiviral Era. Curr. Opin. Gastroenterol. 2017;33:120&#x2013;127. doi: 10.1097/MOG.0000000000000347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000347</ArticleId><ArticleId IdType="pmc">PMC5665375</ArticleId><ArticleId IdType="pubmed">28234770</ArticleId></ArticleIdList></Reference><Reference><Citation>Payer B., Reiberger T., Rutter K., Beinhardt S., Staettermayer A., Peck-Radosavljevic M., Ferenci P. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV&#x2013;HCV coinfected patient. J. Clin. Virol. 2010;49:131&#x2013;133. doi: 10.1016/j.jcv.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.07.006</ArticleId><ArticleId IdType="pubmed">20709593</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun D., Rauch A., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Metzner K.J., B&#xf6;ni J., Weber R., Fehr J. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Med. 2014;15:625&#x2013;630. doi: 10.1111/hiv.12166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.12166</ArticleId><ArticleId IdType="pubmed">24894776</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., M&#xfc;llhaupt B., Metzner K.J., Decosterd L., et al. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE. 2015;10:e0133028. doi: 10.1371/journal.pone.0133028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133028</ArticleId><ArticleId IdType="pmc">PMC4503454</ArticleId><ArticleId IdType="pubmed">26176696</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo J.S., Kim T.-S., Park J.-H., Chi S.-C. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharmacal. Res. 2007;30:82&#x2013;89. doi: 10.1007/BF02977782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02977782</ArticleId><ArticleId IdType="pubmed">17328246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.-W., Lin L.-C., Hung S.-C., Chi C.-W., Tsai T.-H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal. 2007;45:635&#x2013;641. doi: 10.1016/j.jpba.2007.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2007.06.026</ArticleId><ArticleId IdType="pubmed">17692492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.-W., Lin L.-C., Tsai T.-H. Drug&#x2013;drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 2009;121:185&#x2013;193. doi: 10.1016/j.jep.2008.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2008.10.036</ArticleId><ArticleId IdType="pubmed">19041708</ArticleId></ArticleIdList></Reference><Reference><Citation>Weyhenmeyer R., Mascher H., Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992;30:134&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">1572758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd P., Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos) Altern. Med. A J. Clin. Ther. 2005;10:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">16164374</ArticleId></ArticleIdList></Reference><Reference><Citation>Voinovich D., Perissutti B., Grassi M., Passerini N., Bigotto A. Solid State Mechanochemical Activation of Silybum marianum Dry Extract with Betacyclodextrins: Characterization and Bioavailability of the Coground Systems. J. Pharm. Sci. 2009;98:4119&#x2013;4129. doi: 10.1002/jps.21704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21704</ArticleId><ArticleId IdType="pubmed">19226635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosina P., Kren V., Gebhardt R., Grambal F., Ulrichova J., Walterova D. Antioxidant properties of silybin glycosides. Phytother. Res. 2002;16(Suppl. 1):S33&#x2013;S39. doi: 10.1002/ptr.796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.796</ArticleId><ArticleId IdType="pubmed">11933137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira L., Silva M., Manso C. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem. Pharmacol. 1994;48:753&#x2013;759. doi: 10.1016/0006-2952(94)90053-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(94)90053-1</ArticleId><ArticleId IdType="pubmed">8080448</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari H., Agarwal R., Patil C., Katare O.P. Preparation and pharmacological evaluation of silibinin liposomes. Arzneimittelforschung. 2003;53:420&#x2013;427. doi: 10.1055/s-0031-1297130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0031-1297130</ArticleId><ArticleId IdType="pubmed">12872613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Rai A., Reddy N.D., Raj P.V., Jain P., Deshpande P., Mathew G., Kutty N.G., Udupa N., Rao C.M. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol. Rep. 2014;66:788&#x2013;798. doi: 10.1016/j.pharep.2014.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharep.2014.04.007</ArticleId><ArticleId IdType="pubmed">25149982</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F.-Q., Hu J.-H. Improvement of the Dissolution Rate of Silymarin by Means of Solid Dispersions. Chem. Pharm. Bull. (Tokyo) 2004;52:972&#x2013;973. doi: 10.1248/cpb.52.972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.52.972</ArticleId><ArticleId IdType="pubmed">15304992</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M.-F., Jia W., Li S.-S., Xu Z.-H., Sun X., Wang X.-R., Zhang Y.-Y., Xie G.-X. A new silymarin preparation based on solid dispersion technique. Adv. Ther. 2005;22:595&#x2013;600. doi: 10.1007/BF02849953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02849953</ArticleId><ArticleId IdType="pubmed">16510376</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yuan Q., Huang Y., Zhou Y., Liu Y. Development of Silymarin Self-Microemulsifying Drug Delivery System with Enhanced Oral Bioavailability. AAPS PharmSciTech. 2010;11:672&#x2013;678. doi: 10.1208/s12249-010-9432-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-010-9432-x</ArticleId><ArticleId IdType="pmc">PMC2902333</ArticleId><ArticleId IdType="pubmed">20405254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Wang Y., Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 2006;63:288&#x2013;294. doi: 10.1016/j.ejpb.2005.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2005.12.005</ArticleId><ArticleId IdType="pubmed">16527467</ArticleId></ArticleIdList></Reference><Reference><Citation>Parveen R., Baboota S., Ali J., Ahuja A., Ahmad S. Stability studies of silymarin nanoemulsion containing Tween 80 as a surfactant. J. Pharm. Bioallied Sci. 2015;7:321&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678981</ArticleId><ArticleId IdType="pubmed">26681893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Liu Z., Liu G., Duan C., Jia L., Feng F., Zhang X., Shi Y., Zhang Q. In vitroandin vivoevaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology. 2010;21:155104. doi: 10.1088/0957-4484/21/15/155104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0957-4484/21/15/155104</ArticleId><ArticleId IdType="pubmed">20332565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu W.-C., Ng L.-T., Wu T.-H., Lin L.-T., Yen F.-L., Lin C.-C., Huang L.-T. Characteristics and Antioxidant Activities of Silymarin Nanoparticles. J. Nanosci. Nanotechnol. 2012;12:2022&#x2013;2027. doi: 10.1166/jnn.2012.5173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jnn.2012.5173</ArticleId><ArticleId IdType="pubmed">22755015</ArticleId></ArticleIdList></Reference><Reference><Citation>Polyak S.J., Ferenci P., Pawlotsky J.M. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology. 2013;57:1262&#x2013;1271. doi: 10.1002/hep.26179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26179</ArticleId><ArticleId IdType="pmc">PMC3594650</ArticleId><ArticleId IdType="pubmed">23213025</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>